IgA Nephropathy: Clinical Trials

4 trials for IgA Nephropathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 terminated. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Terminated 4

Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
AT-1501 - IgA Nephropathy, IgAN
Phase 2TerminatedEledon Pharmaceuticals242022-03-212024-03-26
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
Telitacicept 160mg, Telitacicept 240mg, Placebo - IgA Nephropathy
Phase 2TerminatedRemeGen Co., Ltd.152021-11-042023-12-06
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
AVB-S6-500 - IgA Nephropathy
Phase 2TerminatedAravive, Inc.12019-11-272022-02-10
Efficacy and Safety of Atacicept in IgA Nephropathy
Placebo, Atacicept 25 mg, Atacicept 75 mg - IgA Nephropathy
Phase 2TerminatedEMD Serono Research & Development Institute, Inc.162017-01-312021-02-25

Narrower conditions

Glomerulonephritis, IGA (4)  ·  Proteinuria (3)  ·  Glomerulonephritis (1)  ·  Kidney Diseases (1)

Broader conditions

Autoimmune Diseases (4)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Immune System Diseases (4)  ·  Male Urogenital Diseases (4)  ·  Nephritis (4)  ·  Urogenital Diseases (4)  ·  Urologic Diseases (4)  ·  Glomerulonephritis (3)  ·  Kidney Diseases (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Signs and Symptoms (3)  ·  Urination Disorders (3)  ·  Urological Manifestations (3)

Interventions

TACI receptor-IgG Fc fragment fusion protein (1)  ·  telitacicept (1)

Sponsors

Aravive, Inc. (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  Eledon Pharmaceuticals (1)  ·  RemeGen Co., Ltd. (1)

Countries

United States (3)  ·  United Kingdom (2)  ·  Australia (1)  ·  Croatia (1)  ·  Japan (1)  ·  Malaysia (1)  ·  New Zealand (1)  ·  Philippines (1)  ·  Poland (1)  ·  Spain (1)  ·  Sri Lanka (1)  ·  Thailand (1)  ·  Ukraine (1)

Top investigators

Francoise Desir (1)

Results publications

PMID 38299639

NIH funding

2016 (1)